Bernardi, F.; Faggiani, I.; Parigi, T.L.; Zilli, A.; Allocca, M.; Furfaro, F.; Peyrin-Biroulet, L.; Danese, S.; D’Amico, F.
JAK Inhibitors and Risk of Cancer in IBD Patients. Cancers 2025, 17, 1795.
https://doi.org/10.3390/cancers17111795
AMA Style
Bernardi F, Faggiani I, Parigi TL, Zilli A, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S, D’Amico F.
JAK Inhibitors and Risk of Cancer in IBD Patients. Cancers. 2025; 17(11):1795.
https://doi.org/10.3390/cancers17111795
Chicago/Turabian Style
Bernardi, Francesca, Ilaria Faggiani, Tommaso Lorenzo Parigi, Alessandra Zilli, Mariangela Allocca, Federica Furfaro, Laurent Peyrin-Biroulet, Silvio Danese, and Ferdinando D’Amico.
2025. "JAK Inhibitors and Risk of Cancer in IBD Patients" Cancers 17, no. 11: 1795.
https://doi.org/10.3390/cancers17111795
APA Style
Bernardi, F., Faggiani, I., Parigi, T. L., Zilli, A., Allocca, M., Furfaro, F., Peyrin-Biroulet, L., Danese, S., & D’Amico, F.
(2025). JAK Inhibitors and Risk of Cancer in IBD Patients. Cancers, 17(11), 1795.
https://doi.org/10.3390/cancers17111795
